OBI Pharma, Inc. (TPEX:4174)

Market Cap	3.28B -54.3%
Revenue (ttm)	52.20M -15.5%
Net Income	-1.53B
EPS	-11.60
Shares Out	131.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	595,784
Open	25.35
Previous Close	24.95
Day's Range	25.00 - 26.35
52-Week Range	24.30 - 66.80
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About OBI Pharma

OBI Pharma, Inc., a clinical stage oncology company, researches and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company’s pipeline products include Adagloxad simolenin, which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424, which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4174

Financial Performance

In 2025, OBI Pharma's revenue was 58.58 million, a decrease of -6.55% compared to the previous year's 62.68 million. Losses were -2.05 billion, -11.13% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error